Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above

NCT03725423 is registered in ClinicalTrials.gov with Xuzhou Central Hospital as lead sponsor.

NCT NCT03725423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03725423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above
Lead sponsor
Xuzhou Central Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
October 31, 2018
Completion date
June 30, 2019
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung squamous cell carcinoma